[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE369427T1 - Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine - Google Patents

Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine

Info

Publication number
ATE369427T1
ATE369427T1 AT02723611T AT02723611T ATE369427T1 AT E369427 T1 ATE369427 T1 AT E369427T1 AT 02723611 T AT02723611 T AT 02723611T AT 02723611 T AT02723611 T AT 02723611T AT E369427 T1 ATE369427 T1 AT E369427T1
Authority
AT
Austria
Prior art keywords
cyanovirins
methods
glycosylated
glycosylation
vectors
Prior art date
Application number
AT02723611T
Other languages
English (en)
Inventor
Michael Boyd
Barry R O'keefe
Toshiyuki Mori
Angela M Gronenborn
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,079 external-priority patent/US6780847B2/en
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE369427T1 publication Critical patent/ATE369427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT02723611T 2001-03-22 2002-03-22 Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine ATE369427T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/815,079 US6780847B2 (en) 1995-04-27 2001-03-22 Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins

Publications (1)

Publication Number Publication Date
ATE369427T1 true ATE369427T1 (de) 2007-08-15

Family

ID=29550490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723611T ATE369427T1 (de) 2001-03-22 2002-03-22 Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine

Country Status (7)

Country Link
US (1) US7339037B2 (de)
EP (1) EP1456382B1 (de)
JP (1) JP4307841B2 (de)
AT (1) ATE369427T1 (de)
AU (1) AU2002254382B2 (de)
CA (1) CA2441287C (de)
DE (1) DE60221705T2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2051730B1 (de) * 2006-08-18 2011-11-02 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Anti-h5n1-influenza-aktivität des antiviralen proteins cyanovirin
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
CN111150724B (zh) * 2020-01-16 2020-12-22 华中农业大学 缬氨酸在制备治疗或预防禽流感病毒感染的药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470067A (en) 1967-09-19 1969-09-30 Pfizer & Co C Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes
US4795740A (en) 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
DE3828842A1 (de) 1988-03-29 1989-10-12 Laube Hans Juergen Verfahren zur behandlung von rna und/oder dna
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
AU633570B2 (en) 1989-04-25 1993-02-04 Tanox Biosystems, Inc. Antibodies specific for cd4-binding domain of hiv
IE904161A1 (en) 1989-11-20 1991-05-22 Oncogen Nonreplicating recombinant-made retroviral particles useful¹as anti-viral agents and as immunogens for prophylaxis and¹therapy against human retroviruses
AU7160691A (en) 1989-12-21 1991-07-24 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
SE9000333D0 (sv) 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
CA2082948C (en) 1990-05-16 2000-07-11 Joseph G. Sodroski Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JP2989862B2 (ja) 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
JPH06502539A (ja) 1990-10-26 1994-03-24 ザ・パブリック・ヘルス・リサーチ・インスティチュート・オブ・ザ・シティ・オブ・ニューヨーク・インコーポレーテッド Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
AU8900691A (en) 1990-11-19 1992-06-11 Queen's University At Kingston Hiv marker/aids vaccine
WO1992008491A1 (en) 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
EP0503916A1 (de) 1991-03-11 1992-09-16 Idec Pharmaceuticals Corporation Verfahren zur Auswahl Antikörperreagenzes; Anti-Idiotype-Antikörper; und Aidsimpfstoffabfassungen
AU1538392A (en) 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
JPH0570493A (ja) 1991-05-31 1993-03-23 Chemo Sero Therapeut Res Inst ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物
KR100251823B1 (ko) 1991-08-22 2000-04-15 안도 고끼 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체
WO1994004574A1 (en) 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
AU2752892A (en) 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
EP0618970A1 (de) 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reaktive neutralisierende humane anti-gp120 rekombinante antikörper, entsprechend kodierende dna und ihre verwendung
EP0581353A1 (de) 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen
DE69332744T2 (de) 1992-09-30 2004-01-15 Scripps Research Inst Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
WO1994028933A1 (en) 1993-06-04 1994-12-22 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
CA2170034C (en) 1993-08-24 2005-03-15 Joseph William Harris Recombinant humanized anti-human immunodeficiency virus antibody
NL9400384A (nl) 1994-03-11 1995-10-02 Smit Victor Retrovirus-vaccins, vaccinatie en immunotherapie tegen retrovirale infecties.
CA2124545A1 (en) 1994-05-27 1995-11-28 Raoul E. Benveniste Method of inducing cell-mediated protective immunity against hiv using low doses of immunogens
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6780847B2 (en) * 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6987096B1 (en) * 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5891444A (en) 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery

Also Published As

Publication number Publication date
US7339037B2 (en) 2008-03-04
JP4307841B2 (ja) 2009-08-05
EP1456382A4 (de) 2004-12-22
EP1456382B1 (de) 2007-08-08
EP1456382A2 (de) 2004-09-15
DE60221705D1 (de) 2007-09-20
JP2004535784A (ja) 2004-12-02
CA2441287C (en) 2014-06-10
CA2441287A1 (en) 2002-10-03
AU2002254382B2 (en) 2007-02-15
DE60221705T2 (de) 2008-06-05
US20040220107A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
EP2258383A3 (de) Von der Telomerase abgeleitete antigene Peptide
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
WO2005118627A3 (en) Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
WO2002101052A3 (en) Salutaridinol 7-o-acetyltransferase and derivatives thereof
ATE369427T1 (de) Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
AU2002307510A1 (en) Cytokine protein family
WO2004091475A3 (en) Gaucher disease drugs and methods of identifying same
WO2002077189A3 (en) Glycosylation-resistant and nonglycosylated cyanovirins
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
EP1038952A3 (de) Verfahren zur Herstellung von Mareks Disease Virus (MDV) unter Verwendung von kontinuierlichen Vogelzellinien
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2000006735A8 (en) Interferon alpha hybrids
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
EP0897984A3 (de) D-Sorbitoldehydrogenase Gen
AU6235000A (en) Method for enhancing rna or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2005019407A3 (en) Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases
DE60041985D1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties